Treatment Algorithm for Managing Chronic Hepatitis B Virus Infection in the United States: 2021 Update

Paul Martin, Mindie H. Nguyen, Douglas T. Dieterich, Daryl T.Y. Lau, Harry L.A. Janssen, Marion G. Peters, Ira M. Jacobson

Research output: Contribution to journalArticlepeer-review

29 Scopus citations


Background & Aims: Chronic hepatitis B (CHB) infection remains the most frequent etiology of hepatocellular carcinoma globally as well as a major cause of cirrhosis. Despite vaccination, substantial numbers of persons have already been infected with hepatitis B virus and remain at risk of progressive liver disease. Methods: In 2004, a CHB management algorithm was developed by a panel of North American hepatologists, which was subsequently updated in 2006, 2008, and 2015. Since the most recent version, several developments have altered the management of CHB. Tenofovir alafenamide, with a more favorable safety profile than tenofovir disoproxil fumarate, has been introduced as an initial antiviral choice as well as an alternative for long-term therapy. Quantitation of hepatitis B surface antigen is becoming more widely available in clinical practice, with implications for monitoring response to treatment. Additionally, there has been a shift in how the natural history of CHB is perceived, as newer evidence has challenged the concept that during the immunotolerant phase of infection disease progression is not a concern. Finally, recent analyses indicate that in the United States, the average age of patients with CHB has increased, implying that the presence of comorbidities, including metabolic liver disease, increasing use of biologics associated with aging will increasingly affect disease management. Results: This updated algorithm is intended to serve as a guide to manage CHB while new antiviral strategies are developed. Conclusions: Recommendations have been based on evidence from the scientific literature, when possible, as well as clinical experience and consensus expert opinion. Points of continued debate and areas of research need are also described.

Original languageEnglish
Pages (from-to)1766-1775
Number of pages10
JournalClinical Gastroenterology and Hepatology
Issue number8
StatePublished - Aug 2022


  • Coinfection
  • Entecavir
  • Peginterferon Alfa
  • Tenofovir


Dive into the research topics of 'Treatment Algorithm for Managing Chronic Hepatitis B Virus Infection in the United States: 2021 Update'. Together they form a unique fingerprint.

Cite this